Related Experiment Video
Updated: May 15, 2025

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Changes in local access to mifepristone dispensed by community pharmacies for medication abortion in Ontario: a
Laura Schummers1, Michael R Law2, Kimberlyn McGrail2
1Collaboration for Outcomes Research and Evaluation (Schummers), Faculty of Pharmaceutical Sciences, University of British Columbia; Centre for Health Services and Policy Research (Law, McGrail), School of Population and Public Health, University of British Columbia, Vancouver, BC; Department of Obstetrics and Gynecology (Darling), McMaster University; ICES McMaster (Darling, Gayowsky), Hamilton, Ont.; Department of Obstetrics & Gynaecology (Zusman), Faculty of Medicine, University of British Columbia, Vancouver, BC; Department of Family and Community Medicine (Dunn), University of Toronto; Women's College Research Institute (Dunn), Women's College Hospital, Toronto, Ont.; Department of Family and Emergency Medicine (Kaczorowski), Université de Montréal, Montréal, Que.; ICES UofT (Gozdyra), Toronto, Ont.; Dalla Lana School of Public Health (Gozdyra), University of Toronto, Toronto, Ont.; Department of Family Practice (Norman), Faculty of Medicine, University of British Columbia, Vancouver, BC; Department of Public Health, Environments and Society (Norman), Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK. laura.schummers@ubc.ca.
Background:
Although mifepristone for medication abortion has been available in Canada since a regulatory change in 2017, leading to its rapid uptake, the effects of this availability on regional access to abortion are unknown. We sought to examine how community pharmacy dispensation of mifepristone affected distribution of abortion services over time in Ontario, Canada.
Methods:
We used linked health administrative data to identify a cohort of all medication and procedural abortions provided in Ontario from 2017 to 2022, defined by outpatient mifepristone dispensations and abortion billing, diagnostic, and procedure codes. We evaluated changes over time in the annual proportion of community pharmacies that dispensed mifepristone and the availability and distribution of medication and procedural abortion services across geographic regions, defined by postal code forward sortation areas.
Results:
In 2017, 2% of Ontario pharmacies filled 1 or more prescriptions for mifepristone, which increased to 20% in 2022. In 2017, few regions contained a mifepristone-dispensing pharmacy (19%) or procedural abortion service (18%). By 2022, most regions had local access to a mifepristone-dispensing pharmacy (77%), with geographically distributed abortion services across Ontario. Although only 37% of abortion service users lived in a region with either a mifepristone-dispensing pharmacy or procedural provider in 2017, this increased to 91% by 2022.
Interpretation:
Access to medication abortion across Ontario increased substantially within 5 years of mifepristone's availability as a normally prescribed and dispensed medication. This regulatory approach appears successful for achieving widespread access to local abortion services.
More Related Videos
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Local Anesthetics: Pharmacokinetics
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...